Key facts
- This page summarizes Blake Borgeson's Form 4 filing for RECURSION PHARMACEUTICALS, INC. (RXRX).
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 05 Jan 2022, 19:39.
Blake Borgeson - 03 Jan 2022 Form 4 Insider Report for RECURSION PHARMACEUTICALS, INC. (RXRX)
- Reporting relationship
- Director
- Issuer ticker
- RXRX
- Reported as of
- 03 Jan 2022
- Net transaction value
- -$173,528
- SEC form
- 4
- Accepted by SEC
- 05 Jan 2022, 19:39:46 UTC
- Prior SEC filing
- 23 Dec 2021
- Next SEC filing
- 05 Apr 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Nathan Hatfield, attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Blake Borgeson filed Form 4 for RECURSION PHARMACEUTICALS, INC. (RXRX) on 05 Jan 2022.
Change
- Previous filing in this sequence was filed on 23 Dec 2021.
- Current net transaction value: -$173,528.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
RXRX
transaction
Class A Common Stock
Award
- Transaction value
- $0
- Shares
- +555
- Change %
- +0.01%
- Price
- $0.000000
- Shares after
- 7,660,771
- Date
- 03 Jan 2022
- Ownership
- Direct
- Footnotes
- F1
RXRX
transaction
Class A Common Stock
Sale
- Transaction value
- $173,528
- Shares
- -9,625
- Change %
- -0.13%
- Price
- $18.03
- Shares after
- 7,651,146
- Date
- 04 Jan 2022
- Ownership
- Direct
- Footnotes
- F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
The shares were issued pursuant to the Issuer's Outside Director Compensation Policy.
Footnote F2
Sales are pursuant to a 10b5-1 trading plan established by the Reporting Person.
Footnote F3
The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $18.00 to $18.08 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request.